about
Targeting of erbB3 receptor to overcome resistance in cancer treatmentProfile of neratinib and its potential in the treatment of breast cancerPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesRegulation of ERBB3/HER3 signaling in cancerOrchestration of ErbB3 signaling through heterointeractions and homointeractions.Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.Comprehensive mutation profiling of mucinous gastric carcinoma.The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilyMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerEpidermal growth factor signaling in transformed cellsComprehensive molecular characterization of urothelial bladder carcinomaPseudokinases: update on their functions and evaluation as new drug targets.A unified model of the hierarchical and stochastic theories of gastric cancer.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer CellsERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells.Receptor tyrosine kinases with intracellular pseudokinase domainsThe E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling.Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach.Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC.Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor.Examination of HER3 targeting in cancer using monoclonal antibodiesProliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPKImmunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genesMolecular biology of bladder cancer.Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodiesERBB3 Positively Correlates with Intestinal Stem Cell Markers but Marks a Distinct Non Proliferative Cell Population in Colorectal Cancer.Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutationsQuantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma.HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-AnalysisHER2 missense mutations have distinct effects on oncogenic signaling and migration.Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patientsExpression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.HER3 over-expression and overall survival in gastrointestinal cancers
P2860
Q26864668-838C7F5E-B407-4E4C-BEE1-A2CB8FB9F528Q27012540-AE46BDB3-FC39-4533-B1AA-D7634DB48B29Q27015224-29855CD4-FB3A-412A-9CCE-1AD9AD794CBCQ27024334-2A36F70B-1F7F-4470-86F7-1CA08E99035BQ27306737-EE9471C2-7CBB-4F25-8B88-0D849E4BFEC8Q27853014-ED42BAE5-2F40-4CEB-A36A-25B461E7233EQ27853392-8E1D098C-8D9A-41C5-BAE9-73B22F01F0B4Q28073335-1759575D-A705-4596-8F8D-61E954F18B6DQ28076490-4073181E-B4FB-4521-A656-04021C220BD7Q28084034-85671FBD-A2B4-4454-8CDF-95401DB83007Q28306864-32F4B685-C565-4A90-8EDC-88EB465B9735Q30397636-5746E8C2-06D5-4BB9-8EA5-F7EB86A9A613Q33577624-E398B6EF-FCC5-4F23-8B3F-7D8F4B6A2DD9Q33601653-BE01A822-3D67-48C5-BA74-658BCD3FC644Q33605906-55A705DD-86C3-48FA-B3EC-7417502EE728Q33691823-8ABAEE6B-4C65-4054-82D3-D7D98530CF38Q33772914-C25DE38A-E05B-46CE-840F-244F32AB3A38Q34104165-6B131D59-D9F8-4F6D-A0F5-002B5CE5EB9FQ34358042-E783880E-BE13-49BE-9DFC-DB6C64F368CCQ34411756-08BB63F9-6FB0-4712-BE16-D9C092013F83Q34423170-0A1AFB31-DE50-4321-BACE-1489F74A812CQ34471813-B169CAC1-B3CC-4713-AD55-23D95B05AD37Q34619329-A9F6A3CC-FE87-4251-9BC5-A1A16EFEBBB2Q34625617-DBC0058C-5B58-4F4D-BC04-E76E73014C81Q35031462-79E3BD0A-515B-4780-BD63-80D94B88392FQ35036012-8811E9DB-A81D-4DD3-AA83-25FD85FBAE5DQ35051995-7523EB55-3D85-42E1-BF73-6373BAB577CAQ35160677-8CF04A71-B4AE-469C-B646-3963C871D87BQ35266400-D0659492-EF63-4BA9-A3F5-00FDC0373194Q35409548-2D845C6D-FC76-4F7C-9CC6-EA0C9DCB3780Q35772903-B4DBE3B0-C615-4BF5-B649-2CBF00401A2CQ35820920-1302A302-1C09-4070-AACF-9D082D0E764DQ35888647-FB3080F8-AFAE-4FE5-B0B9-9A5CA41FC4EDQ35926362-810D6320-73C0-45E8-8D8C-8BD43F01B9ADQ36088709-BCE44FF0-8CF4-495A-A974-1099650F8C29Q36106546-9B01802B-51F1-40B9-8C38-37E0B7D57572Q36300320-AFBBAFF3-134A-4591-91CD-0F7DC009B236Q36544077-2CFDF2DB-927C-4647-AC58-8A7868098246Q36547753-5ECF8A14-D668-47E2-B6B6-055400969BEBQ36619051-FC24E76A-8D77-4E11-BCD0-884FC5D1E621
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Oncogenic ERBB3 mutations in human cancers
@ast
Oncogenic ERBB3 mutations in human cancers
@en
Oncogenic ERBB3 mutations in human cancers
@en-gb
Oncogenic ERBB3 mutations in human cancers
@nl
type
label
Oncogenic ERBB3 mutations in human cancers
@ast
Oncogenic ERBB3 mutations in human cancers
@en
Oncogenic ERBB3 mutations in human cancers
@en-gb
Oncogenic ERBB3 mutations in human cancers
@nl
prefLabel
Oncogenic ERBB3 mutations in human cancers
@ast
Oncogenic ERBB3 mutations in human cancers
@en
Oncogenic ERBB3 mutations in human cancers
@en-gb
Oncogenic ERBB3 mutations in human cancers
@nl
P2093
P50
P3181
P1433
P1476
Oncogenic ERBB3 mutations in human cancers
@en
P2093
Bijay S Jaiswal
Chaitali Parikh
Emily Chan
Eric W Stawiski
Frederic J de Sauvage
Gabriele Schaefer
Howard M Stern
Jeremy Stinson
Jiansheng Wu
P304
P3181
P356
10.1016/J.CCR.2013.04.012
P407
P577
2013-05-13T00:00:00Z